Open AccessCXCR4 Expression in Prostate Cancer Progenitor Cells
Author(s) -
Anna Dubrovska,
Jimmy Elliott,
Richard J. Salamone,
Г. Д. Телегеев,
Alexander E. Stakhovsky,
I. B. Schepotin,
Feng Yan,
Yan Wang,
Laure C. Bouchez,
Sumith A. Kularatne,
J. P. Watson,
Christopher Trussell,
Venkateshwar A. Reddy,
Charles Y. Cho,
Peter G. Schultz
Publication year - 2012
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0031226
Subject(s) - prostate cancer , cancer research , cancer stem cell , metastasis , progenitor cell , cd44 , cxcr4 , prostate , population , stem cell , cancer , biology , plerixafor , progenitor , medicine , oncology , cell , receptor , microbiology and biotechnology , chemokine , genetics , environmental health
Tumor progenitor cells represent a population of drug-resistant cells that can survive conventional chemotherapy and lead to tumor relapse. However, little is known of the role of tumor progenitors in prostate cancer metastasis. The studies reported herein show that the CXCR4/CXCL12 axis, a key regulator of tumor dissemination, plays a role in the maintenance of prostate cancer stem-like cells. The CXCL4/CXCR12 pathway is activated in the CD44 + /CD133 + prostate progenitor population and affects differentiation potential, cell adhesion, clonal growth and tumorigenicity. Furthermore, prostate tumor xenograft studies in mice showed that a combination of the CXCR4 receptor antagonist AMD3100, which targets prostate cancer stem-like cells, and the conventional chemotherapeutic drug Taxotere, which targets the bulk tumor, is significantly more effective in eradicating tumors as compared to monotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom